Cardiovascular (CV) disease is the leading cause of morbidity and mortality in the United States end-stage renal disease (ESRD) population. Annually, approximately 30% of hospitalizations and 50% of deaths are attributed to CV causes. 1 The etiology of CV disease among individuals receiving maintenance hemodialysis differs from that of the general population. Dialysis-specific risk factors such as repeated, large intradialytic fluid, and blood pressure (BP) shifts likely play substantial pathologic roles in dialysis-associated CV risk. Typical systolic BP behavior during hemodialysis is characterized by 2 phases, a relatively rapid BP decline in the first quarter of the treatment followed by a more gradual BP decline in the latter 75% of treatment. 2 Deviations from the typical BP course such as intradialytic hypotension (a precipitous BP drop during hemodialysis) and intradialytic hypertension (a paradoxical predialysis to postdialysis BP rise also known as postdialysis hypertension) have been associated with increased morbidity and mortality. [3] [4] [5] [6] [7] Of the 2 BP abnormalities, intradialytic hypertension has received comparatively less attention.
It is plausible that patients who experience intradialytic hypertension more frequently may be at increased risk for short-term hypervolemic repercussions such as flash pulmonary edema, and consequent hospitalizations and mortality. Thus, frequent intradialytic hypertension could be an important risk marker for short-term adverse events. To our knowledge, no prior studies have examined the associations between intradialytic hypertension frequency and shortterm CV morbidity and mortality.
We undertook this study to investigate the association between intradialytic hypertension frequency and 30-day: (i) all-cause and CV mortality and (ii) all-cause, CV, and fluid-related hospitalizations in a large, nationally representative cohort of prevalent hemodialysis patients treated at a large dialysis organization in the United States.
METHODS

Study data, design, and population
We conducted an observational study in a point prevalent cohort of ESRD patients receiving in-center, thrice-weekly hemodialysis at a large, United States dialysis organization on 1 January 2010. The dialysis organization operates over 1,500 outpatient dialysis clinics throughout the nation. Its clinical database captures detailed demographic, clinical, laboratory, and dialysis treatment data. Laboratory data are measured on a biweekly or monthly basis. Hemodialysis treatment parameters, including predialysis and postdialysis BPs, are recorded on a treatment-to-treatment basis. The dialysis organization data were linked at the patient-level to the United States Renal Data System (USRDS), a national ESRD surveillance system. The USRDS data includes: the Medical Evidence Report Form (a patient history and registration form completed upon enrollment into the Medicare ESRD program), Medicare Enrollment database (a repository of Medicare beneficiary enrollment and entitlement data), ESRD Death Notification Form (the official form for reporting deaths), and Medicare standard analytic files (final action administrative claims data including Medicare Parts A, B and D). 14 Figure 1 provides an overview of the study design. Briefly, we used a retrospective cohort design with a 180-day baseline period, 30-day exposure assessment period, and 30-day follow-up period to investigate the associations between intradialytic hypertension frequency and shortterm clinical outcomes. Patients were included in this study if they: (i) were 18 years of age or older; (ii) had been on maintenance dialysis for at least 1 year; (iii) had at least 7 clinic-based hemodialysis treatments during the exposure period; and (iv) had Medicare Part A, B, and D coverage with Medicare as their primary payer during the baseline and exposure periods. Patients who received peritoneal or home hemodialysis during the baseline or exposure periods were excluded.
This study was approved by the University of North Carolina at Chapel Hill Institutional Review Board (#15-2651). A waiver of consent was granted due to the study's large cohort size, data anonymity, and retrospective nature. 
Exposure assessment
A single dialysis treatment was considered complicated by intradialytic hypertension if there was a predialysis to postdialysis systolic BP rise (postdialysis systolic BP minus predialysis systolic BP >0 mm Hg). 15 For each patient, the proportion of exposure period treatments affected by intradialytic hypertension was computed as: [(number of exposure period dialysis treatments with a change in systolic BP from predialysis to postdialysis >0 mm Hg)/(total number of dialysis treatments in the exposure period)] × 100%. Intradialytic hypertension frequency was parameterized as a multilevel categorical variable: 0%, 1-32%, 33-66%, and ≥67% of exposure period treatments with intradialytic hypertension. [16] [17] [18] 
Outcome ascertainment
The primary outcomes of interest were: 30-day allcause and CV mortality, and 30-day all-cause, CV and Values are given as number (percentage) for categorical variables and as mean ± SD for continuous variables. Abbreviations: ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; ESRD, end-stage renal disease; SBP, systolic blood pressure. a In primary analyses, a single episode of intradialytic hypertension was defined as a predialysis to postdialysis systolic BP rise >0 mm Hg. b Intradialytic hypotension, low blood pressure during dialysis, was defined using the Flythe et al. definition. 3 Patients were considered as having baseline intradialytic hypotension if they had an intradialytic nadir systolic blood pressure <90 mmHg in at least 30% of outpatient dialysis treatments in the last 30 days of the baseline period. c Values were imputed using Markov chain Monte Carlo method using 10 imputations when missing (n = 656 for albumin, n = 374 for calcium, n = 388 for phosphorus, n = 2,243 for creatinine, n = 48 for hemoglobin, and n = 388 for equilibrated Kt/V). d Hospitalized in the last 30 days of the baseline period. e Dialyzable antihypertensive medications include: acebutolol, atenolol, captopril, enalapril, lisinopril, methyldopa, metoprolol, minoxidil, nadolol, perindopril, sotalol, trandolapril. [23] [24] [25] volume-related hospitalizations. Consistent with the USRDS definition, CV mortality was defined as a death due to: acute myocardial infarction, pericarditis including cardiac tamponade, atherosclerotic heart disease, cardiomyopathy, cardiac arrhythmia, cardiac arrest, valvular heart disease, pulmonary edema, congestive heart failure, pulmonary embolus, or stroke. 14 CV hospitalizations were identified using the established USRDS claims-based definition. 14 Volume-related hospitalizations were identified using a previously validated claims-based definition. 19 Supplementary Table 1 displays detailed outcome definitions.
Baseline covariate determination
Demographic characteristics and comorbid conditions were identified using USRDS data (Supplementary Table 2 ). Laboratory and dialysis treatment covariates were identified using the dialysis organization's clinical database. Laboratory variables and vascular access type were considered as the last baseline value. Predialysis systolic BP, interdialytic weight gain, and dialysis treatment time were considered as the mean of values in the last 30 days of the baseline period. Patients were considered to have a recent history of intradialytic hypotension if their nadir intradialytic systolic BP was <90 mm Hg in at least 30% of outpatient dialysis treatments during the last 30 days of the baseline period. 3 Hospitalizations that occurred in the last 30 days of the baseline period were identified using Medicare Part A claims. Baseline utilization of antihypertensive medications was ascertained using USRDS Medicare Part D claims. Patients were considered to be taking a specific antihypertensive medication if the days supply of a prescription fill overlapped with the last day of the baseline period.
Statistical analysis
All analyses were performed using SAS, version 9.4 (SAS Institute, Cary, NC). Baseline patient characteristics are described in the overall study population and across intradialytic hypertension frequency groups as count (percentage) for categorical variables and mean ± SD for continuous variables.
In primary analyses, we assessed the association between intradialytic hypertension frequency and 30-day all-cause and CV mortality, and 30-day all-cause, CV and volumerelated hospitalizations (separately). Adjusted hazard ratios and 95% confidence intervals were estimated with multivariable Cox proportional hazards regression models. Study follow-up began immediately after the 30-day exposure assessment period. Patients surviving the exposure period were followed forward in historical time to the first occurrence of a study outcome or censoring event. Censoring events included: kidney transplantation, dialysis modality change to home hemodialysis or peritoneal dialysis, loss of Medicare Part A/B coverage, no longer treated at one of the large dialysis organization's facilities, or end of the 30-day follow-up period. In hospitalization analyses, death was treated as a censoring event. Missing covariate values were imputed using the Markov chain Monte Carlo method with 10 imputations (n = 656 for albumin, n = 374 for calcium, n = 388 for phosphorus, n = 2,243 for creatinine, n = 48 for hemoglobin, and n = 388 for equilibrated Kt/V (small solute clearance). 20 In exploratory secondary analyses, we evaluated effect modification of intradialytic hypertension-outcome associations (all-cause mortality and hospitalizations) on the basis of sex (males vs. females), race (Black vs. non-Black), antihypertensive medication classification (use of ≥1 dialyzable BP medication vs. not), weekly erythropoietin simulating agent dose (≥75 th vs. <75 th percentile) using restriction subgroup Figure 3 . Association between intradialytic hypertension frequency and 30-day mortality. A single episode of intradialytic hypertension was defined as a predialysis to postdialysis systolic BP rise >0 mm Hg. Multivariable Cox proportional hazards models were used to estimate the associations between intradialytic hypertension frequency and all-cause mortality (a) and cardiovascular mortality (b). Models were adjusted for the baseline covariates listed in Table 1 . All y-axes scales are natural log transformed. Abbreviations: BP, blood pressure; CI, confidence interval; HR, hazard ratio; ref, referent.
analyses. Significance of interaction was assessed by the Wald test of nested models that did and did not include 2-way cross-product terms.
We conducted sensitivity analyses to assess the robustness of our primary results. First, we expanded the study followup period to assess 60-and 90-day outcomes. Second, we considered alternative thresholds of predialysis to postdialysis systolic BP rise (≥5 mm Hg and ≥10 mm Hg) to identify exposure period treatments complicated by intradialytic hypertension. 5, 7, 11 Finally, we found that 854 (2.3%) of individuals had hospitalizations that extended from the exposure period into the follow-up period. We thus repeated primary analyses excluding these individuals. characteristics are presented in Table 1 . Study patients had an average age of 59.3 ± 14.9 years, 47.1% were female, 44.3% were Black and the most common cause of ESRD was diabetes (44.5%). The study cohort was comparable to the broader United States hemodialysis population in terms of age, sex and ESRD cause. 1 Of the 37,094 study patients, 5,242 (14.1%) did not experience intradialytic hypertension (a predialysis to postdialysis systolic BP rise >0 mm Hg) during the exposure period. A total of 17,965 (48.4%), 10,821 (29.2%), and 3,066 (8.3%) patients exhibited intradialytic hypertension in 1-32%, 33-66%, and ≥67% of exposure period hemodialysis treatments, respectively. Individuals with more frequent intradialytic hypertension tended to be older and female, and were more likely to have diabetes, hypertension, heart failure, dialysis treatment times <240 minutes, miss more outpatient dialysis treatments, be prescribed at least 1 dialyzable antihypertensive medication, and utilize higher weekly doses of erythropoietin compared to individuals with less frequent intradialytic hypertension.
RESULTS
Study cohort characteristics
Primary analyses
During the 30-day follow-up period, there were 476 allcause (15.7/100 person-years) and 215 CV (7.1/100 person-years) deaths. Figure 3 depicts the association between intradialytic hypertension frequency and 30-day all-cause and CV mortality. More frequent intradialytic hypertension was associated with incremental increases in 30-day all-cause and CV mortality. Patients who experienced intradialytic hypertension in ≥67% (vs. 0%) of exposure period treatments had the highest hazard for death (adjusted hazard ratio [95% confidence interval]: 2.57 [1.68, 3 .94] for all-cause mortality and 3.68 [1.89, 7.15] for CV mortality). Subgroup analyses evaluating the association between intradialytic hypertension frequency and all-cause mortality across strata of sex, race, dialyzable antihypertensive medication use, and erythropoiesis stimulating agent (ESA) dose produced consistent results (Table 2) .
During the 30-day follow-up period, there were 5,091 all-cause (181.0/100 person-years), 1,639 CV (55.5/100 person-years), and 232 volume-related (7.7/100 person-years) hospitalizations. Figure 4 illustrates the association between intradialytic hypertension frequency and 30-day all-cause, CV, and volume-related hospitalizations. Similar to mortality, patients with more frequent (vs. less frequent) intradialytic hypertension had a higher hazard of initial all-cause, CV, and volume-related hospitalizations. Subgroup analyses evaluating the association between intradialytic hypertension frequency and all-cause hospitalizations across strata of sex, race, dialyzable antihypertensive medication use, and ESA dose produced consistent results (Table 2) .
Sensitivity analyses
Sensitivity analyses considering 60-and 90-day outcomes yielded results analogous to primary analyses (Table 3) . Experiencing a predialysis to postdialysis systolic BP rise >0 mm Hg more (vs. less) frequently was associated with greater 60-and 90-day mortality and hospitalizations. Employing alternative systolic BP thresholds (predialysis to postdialysis systolic BP rise ≥5 mm Hg and ≥10 mm Hg) to define episodes of intradialytic hypertension resulted in findings similar to primary analyses (Table 4 ). More frequent intradialytic hypertension, regardless of systolic BP threshold used, was associated with increased 30-day all-cause and CV mortality and 30-day all-cause, CV, and volume-related hospitalizations. Sensitivity analyses excluding individuals who had a hospitalization that extended from the exposure period into the follow-up period also yielded results similar to primary analyses (Supplementary Table 3 ).
DISCUSSION
To our knowledge, this is the first study demonstrating an association between intradialytic hypertension and an increased risk of 30-day mortality and hospitalizations. We demonstrated that more frequent intradialytic hypertension was associated with incremental increases in 30-day mortality (all-cause and CV) and hospitalizations (all-cause, CV, and volume-related). Our findings were robust across different: lengths of study follow-up, definitions of intradialytic hypertension, and clinically relevant subgroups.
Prior observational studies have shown an association between intradialytic hypertension and long-term mortality. In a cohort of incident United States hemodialysis patients, Inrig et al. found that every 10 mm Hg increase in predialysis to postdialysis systolic BP was associated with a 6% increase in the 2-year all-cause mortality rate. 6 In a prospective study of 115 Taiwanese hemodialysis patients, Yang et al. reported that an average change in systolic BP from predialysis to postdialysis >5 mm Hg (vs. ≤5 mm Hg) was associated with higher 4-year all-cause mortality. 7 In a retrospective analysis of 3,196 Italian hemodialysis patients without heart failure, Losito et al. noted that an average predialysis to postdialysis systolic BP change >10 mm Hg (vs. a BP change between −20 mm Hg and 10 mm Hg) was associated increased CV mortality over a mean follow-up time of 26.8 months. 11 In the largest observational study to date (N = 113,255), Park et al. demonstrated that a predialysis to postdialysis systolic BP rise was incrementally associated with greater all-cause and CV mortality over a median follow-up time of 2.2 years. 10 Abbreviations: BP, blood pressure; CI, confidence interval; HR, hazard ratio. a A single episode of intradialytic hypertension was defined as a predialysis to postdialysis systolic BP rise >0 mm Hg. b Multivariable Cox proportional hazards models were used to estimate the associations between intradialytic hypertension frequency and each clinical outcome. Models were adjusted for the baseline covariates listed in Table 1 .
Less data exist regarding intradialytic hypertension and short-term outcomes. In a post-hoc analysis of the Crit-Line Intradialytic Monitoring Benefit Study, Inrig et al. found that patients with an average increase in predialysis to postdialysis systolic BP ≥10 mm Hg (vs. <10 mm Hg) had roughly 2 times the odds of a composite outcome of nonvascular access-related hospitalization or death at 6 months. 5 Our findings of an incremental association between intradialytic hypertension frequency and the occurrence of 30-day hospitalizations and mortality support and expand the evidence-base.
In the studies highlighted above, intradialytic hypertension was specified as a mean-based exposure, whereby the predialysis to postdialysis systolic BP changes from individual hemodialysis treatments were averaged at the patientlevel over varying exposure assessment period lengths (ranging from 1 week to 3 months). [5] [6] [7] 10 However, arithmetic means are sensitive to extreme values, and outliers may overinfluence results. Such an effect is more likely when fewer BP measurements (i.e., shorter exposure assessment periods) are used to characterize mean-based intradialytic hypertension. In addition, mean-based exposure definitions may obscure outcome associations in settings where both positive (BP rise) and negative (BP fall) values may occur. Alternatively, we defined intradialytic hypertension using a frequency-based approach. This strategy may better capture the physiologic burden of repeated intradialytic hypertension episodes. Unlike mean-based intradialytic hypertension definitions, utilization of a frequency-based definition also facilitates study of an abnormal intradialytic BP phenotype that can be easily identified in routine clinical practice.
Numerous pathophysiologic mechanisms including volume overload, endothelial dysfunction, sympathetic nervous system overactivity, and renin-angiotensin-aldosterone system activation may play roles in the pathogenesis of intradialytic hypertension. Intradialytic hypertension is often attributed to volume overload. In a cross-sectional study, Nongnuch et al. reported that patients who experienced a predialysis to postdialysis systolic BP rise (vs. not) had higher predialysis and postdialysis extracellular water to total body water ratios and lower ultrafiltration volumes. 12 Additionally, intensification of ultrafiltration has been shown to improve BP, ejection fraction, and cardiac output among individuals with intradialytic hypertension. 15 Our data provide further support for a link between volume status and intradialytic hypertension. We found that patients who experienced more frequent intradialytic hypertension had an incrementally higher hazard of 30-day volume-related hospitalizations.
Beyond volume overload, endothelial dysfunction may also contribute to the development of intradialytic hypertension. Among hemodialysis patients prone to intradialytic hypertension, serum endothelin-1 (a vasoconstrictor) concentrations tend to rise during dialysis, and compensatory serum nitric oxide (a vasodilator) levels remain low, resulting in increased peripheral vascular resistance. 17 Historically, ESA use was a notable contributor to intradialytic hypertension via its dose-dependent influence on endothelin-1 production. 21 In the modern era of restricted ESA dosing, the role of ESAs in the development of intradialytic hypertension is likely diminished. Additionally, another modifiable factor that may be involved in the development of intradialytic hypertension is the utilization of antihypertensive medications that are extensively cleared by hemodialysis. Our findings potentially support this idea. We observed that dialyzable BP medication use was more common among patients experiencing more frequent intradialytic hypertension. However, dialyzable antihypertensive medication use (vs. non-dialyzable antihypertensive medication use) did not significantly modify the association between intradialytic hypertension frequency and 30-day all-cause mortality and hospitalizations.
Our results indicate that intradialytic hypertension may be a risk marker for impending adverse events secondary to volume overload and suggest that prompt volume assessment among hemodialysis patients who experience frequent episodes of intradialytic hypertension is warranted. In fact, challenging prescribed target (estimated "dry") weight via increased ultrafiltration has been shown to improve intradialytic hypertension. 22 Other interventions that promote postdialysis euvolemia, such as extending dialysis treatment times and the provision of extra dialysis treatments, may also be helpful. For patients who remain prone to recurrent intradialytic hypertension despite volume challenge, antihypertensive medication regimens should be re-evaluated. The practice of withholding antihypertensive medications prior to dialysis treatments may promote a predialysis to postdialysis BP rise. Additionally, it may be prudent to avoid dialyzable antihypertensive medications. For example, carvedilol is not extensively removed by dialysis [23] [24] [25] and has been shown to modestly improve vascular endothelial function and reduce the occurrence of intradialytic hypertension. 26 Our study has many strengths. We utilized data from a large, contemporary cohort with detailed clinical and administrative claims data and, we chose a study design with discrete baseline, exposure and follow-up periods to minimize immortal person time and selection biases. Additionally, we identified intradialytic hypertension using a clinically applicable, frequency-based definition. However, our results should be considered in the context of study limitations. First, our study was observational, and it is possible that residual confounding may exist. To minimize the influence of confounding from difficult-to-measure factors such as ambient health status, we controlled for variables including albumin, phosphorus, and creatinine. Nonetheless, it is possible that our results could have been confounded by unmeasured differences across intradialytic hypertension frequency groups. Second, predialysis and postdialysis BP measurements were taken during routine clinical care and were not standardized. Finally, our study included adult, center-based hemodialysis patients with dialytic vintage of 1 year or longer. Results should not be extrapolated to excluded populations such as incident dialysis patients.
In conclusion, we demonstrated that the occurrence of more frequent intradialytic hypertension was associated with incremental increases in 30-day mortality and hospitalizations among prevalent hemodialysis patients. Our data indicate that intradialytic hypertension may be an important short-term risk marker in the hemodialysis population.
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